3599 |
Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR) |
Alan C. Yeung |
Apr. 28. 18 |
3598 |
Where to with Cerebral Protection in TAVI? |
Horst Sievert |
Apr. 28. 18 |
3597 |
TAVR vs SAVR in 2018: Updated Guidelines and Appropriate Use Criteria |
Eberhard Grube |
Apr. 28. 18 |
3596 |
Transcatheter Aortic Valve Replacement(TAVR) - Lessons on the Natural History of Aortic Stenosis |
James Flaherty |
Apr. 28. 18 |
3595 |
STEMI with Shock: The Culprit-Shock Trial Challenges Current Guidelines |
Jacques J. Koolen |
Apr. 28. 18 |
3594 |
STEMI with MVD: An Ongoing Battle for the Optimal Treatment Strategy |
Neal S. Kleiman |
Apr. 28. 18 |
3593 |
Stable CAD & PAD: COMPASS Trial - Will It Change Practice? |
David Joel Cohen |
Apr. 28. 18 |
3592 |
DAPT Dilemmas in ACS: Where to Go - Shorter vs. Longer Durations? |
Tullio Palmerini |
Apr. 28. 18 |
3591 |
Non-Invasive FFR Assessment |
William F. Fearon |
Apr. 28. 18 |
3590 |
Implications of Hospital-Level Variation in FFR Severity on Cost Effectiveness |
Nils Johnson |
Apr. 28. 18 |